NuPathe (PATH) on the Radar on Sector Deal
Traders are eying NuPathe, Inc. (Nasdaq: PATH) after Allergan, Inc. (NYSE: AGN) agreed to acquire MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) for $25 per share, or a 60% premium.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Riverbed (RVBD) Attracts PE Interest, to Contact Buyers in A Week, Says DealReporter
- TheStreetSweeper Negative on iBio, Inc. (IBIO)
- GT Advanced Technologies (GTATQ), Apple Enter Settlement Agreement
Create E-mail Alert Related CategoriesRumors, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!